Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.
Biocon has appointed Christiane Hamacher as CEO of Biocon Biologics India. With “more than 20 years of leadership experience in both strategic and operational roles across the value chain in global pharma, spanning Asia, Europe and the US”, Hamacher joins from Roche, where she worked for over eight years, most recently as head of the Asia-Pacific region for Pharma.
Citing her “long career in the pharmaceutical industry”, the Indian firm noted that Hamacher had “built experience in the areas...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
